SCHEMBL1031827

SCHEMBL1031827

NC(=O)CCC(F)F

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1031632 0.86
SCHEMBL1030136 0.78
SCHEMBL15646924 0.78 ALOX15 (0.46)
SCHEMBL3510953 0.76 KMT2A (0.56)
SCHEMBL30530245 0.73 ALOX15 (0.59)
SCHEMBL10898287 0.73
SCHEMBL158888 0.73
SCHEMBL1032359 0.73
SCHEMBL22278091 0.73
SCHEMBL1032360 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117500507-A Phosphorus derivatives as novel SOS1 inhibitors 拜耳公司 2024-02-02 CN claimed
WO-2009129548-A1 ANTIOXIDANT INFLAMMATION MODULATORS: C-17 HOMOLOGATED OLEANOLIC ACID DERIVATIVES REATA PHARMACEUTICALS, INC. (US) 2009-10-22 WO claimed
EP-4408530-A1 BENZIMIDAZOLES AS MODULATORS OF IL-17 Janssen Pharmaceutica NV (BE) 2024-08-07 EP disclosed
CN-117500507-A Phosphorus derivatives as novel SOS1 inhibitors 拜耳公司 2024-02-02 CN disclosed
WO-2023049888-A1 BENZIMIDAZOLES AS MODULATORS OF IL-17 JANSSEN PHARMACEUTICA NV (BE) 2023-03-30 WO disclosed
EP-3180308-B1 METHOD FOR PRODUCING 2,2-DIFLUOROETHYLAMINE BASF SE (DE) 2018-04-18 EP disclosed
EP-3180308-A1 METHOD FOR PRODUCING 2,2-DIFLUOROETHYLAMINE BASF SE (DE) 2017-06-21 EP disclosed
WO-2016023773-A1 METHOD FOR PRODUCING 2,2-DIFLUOROETHYLAMINE BASF SE (DE) 2016-02-18 WO disclosed
EP-2855451-A1 HETEROCYCLYL PYRIMIDINE ANALOGUES AS TYK2 INHIBITORS Cellzome Limited (GB) 2015-04-08 EP disclosed
US-8969552-B2 Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor AbbVie Deutschland GmbH & Co. KG (DE) 2015-03-03 US disclosed
EP-2439203-B1 Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor ABBVIE DEUTSCHLAND (DE) 2014-11-19 EP disclosed
EP-1807392-A1 6-AMINO(AZA)INDANE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECPTOR Abbott GmbH & Co. KG (DE) 2007-07-18 EP disclosed
WO-2006040178-A9 ARYLSULFONYLMETHYL OR ARYLSULFONAMIDE SUBSTITUTED AROMATIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MADULATION OF THE DOPAMINE D3 RECEPTOR ABBOTT GMBH & CO KG (DE) 2007-04-19 WO disclosed
US-20070015759-A1 Metasubstituted thiazolidinones, their manufacture and use as a drug BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-01-18 US disclosed
WO-2006040177-A1 6-AMINO(AZA)INDANE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECPTOR ABBOTT GMBH & CO.KG (DE) 2006-04-20 WO disclosed
WO-2006040180-A1 AMINOMETHYL SUBSTITUTED BICYCLIC AROMATIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR ABBOTT GMBH & CO. KG (DE) 2006-04-20 WO disclosed
WO-2006040178-A1 ARYLSULFONYLMETHYL OR ARYLSULFONAMIDE SUBSTITUTED AROMATIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MADULATION OF THE DOPAMINE D3 RECEPTOR ABBOTT GMBH & CO.KG (DE) 2006-04-20 WO disclosed
WO-2006040176-A1 AZABICYCLOHEPTYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR ABBOTT GMBH & CO. KG (DE) 2006-04-20 WO disclosed
WO-2006040179-A1 AMINOETHYLAROMATIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR ABBOTT GMBH & CO. KG (DE) 2006-04-20 WO disclosed
US-4609648-A SYNERGISTS FOR ARTHROPODICIDES BAYER AKTIENGESELLSCHAFT (DE) 1986-09-02 US disclosed